Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT-planned dose-escalated chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
2005-006097-10Phase 2Recruiting
- Sponsor
- Universitätsmedizin Essen
- Start
- Mar 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, fluorouracil, irinotecan and folinic acid in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Universitätsmedizin Essen. Primary endpoints: Local progression-free survival at 1 year and Improvement of local tumor control. Started Mar 2006; status: recruiting.
02
Drugs
cisplatinfluorouracilirinotecanfolinic acid
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2005-006097-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006097-10.